On September 24, 2013, FDA conducted a public meeting on Patient-Focused Drug Development for narcolepsy. FDA is interested in obtaining patient input on the impact of narcolepsy on daily life and the available therapies for narcolepsy
September 24, 2013
1 p.m. to 5 p.m.
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503A
Silver Spring, MD 20993
(Information about arrival to FDA's White Oak campus)
To register for this meeting, visit: http://patientfocusednarcolepsy.eventbrite.com
Registration closed on September 13, 2013.
Submitting comments to the docket: In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. Visit the following website to provide electronic or written comments: http://www.regulations.gov/#!submitComment;D=FDA-2013-N-0815-0001.
Alternatively, you can submit comments through fax or mail. Fax comments to the Division of Dockets Management at 301-827-6870, or mail comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should include the docket number FDA-2013-N-0815.